Cargando…

Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011

The aim of this work was to describe national surveillance of invasive beta-haemolytic streptococci (BHS) in Denmark and to report overall trends and major findings by groups and types of BHS causing laboratory-confirmed disease from 2005 to 2011. A total of 3063 BHS isolates were received from 2872...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambertsen, L M, Ingels, H, Schønheyder, H C, Hoffmann, S, Mainardi, J-L, Danish Streptococcal Surveillance Collaboration Group 2011
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232002/
https://www.ncbi.nlm.nih.gov/pubmed/24125634
http://dx.doi.org/10.1111/1469-0691.12378
_version_ 1782344512323977216
author Lambertsen, L M
Ingels, H
Schønheyder, H C
Hoffmann, S
Mainardi, J-L
Danish Streptococcal Surveillance Collaboration Group 2011,
author_facet Lambertsen, L M
Ingels, H
Schønheyder, H C
Hoffmann, S
Mainardi, J-L
Danish Streptococcal Surveillance Collaboration Group 2011,
author_sort Lambertsen, L M
collection PubMed
description The aim of this work was to describe national surveillance of invasive beta-haemolytic streptococci (BHS) in Denmark and to report overall trends and major findings by groups and types of BHS causing laboratory-confirmed disease from 2005 to 2011. A total of 3063 BHS isolates were received from 2872 patients. Based on confirmed cases the overall annual incidence increased from 6.2 to 8.9 per 100 000 persons between 2005 and 2011. In 2011 the incidences of group A, B, C and G streptococci were 3.1, 2.3, 0.9 and 2.6 per 100 000 persons, respectively. An increase was observed for all groups of BHS, but in particular for group G in men above 65 years of age. Among group A streptococci (GAS), five T-types (1, 28,12, 3,13,B3264 and B3264) represented 71% and five emm-types (1, 28, 3, 89 and 12) 76% of all isolates. Among group B streptococci (GBS) four types (III, Ia, V, Ib) represented 79% of the isolates. Potential coverage for future vaccines against GAS and GBS disease was 76% compared with the 26-valent GAS vaccine and 89% based on GBS serotypes Ia, Ib, II, III and V. The number of reported cases of invasive BHS disease increased in Denmark from 2005 to 2011. Nationwide laboratory-based surveillance of BHS is required to monitor epidemiological changes, explore potential outbreaks and determine potential vaccine coverage.
format Online
Article
Text
id pubmed-4232002
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42320022014-12-15 Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011 Lambertsen, L M Ingels, H Schønheyder, H C Hoffmann, S Mainardi, J-L Danish Streptococcal Surveillance Collaboration Group 2011, Clin Microbiol Infect Epidemiology The aim of this work was to describe national surveillance of invasive beta-haemolytic streptococci (BHS) in Denmark and to report overall trends and major findings by groups and types of BHS causing laboratory-confirmed disease from 2005 to 2011. A total of 3063 BHS isolates were received from 2872 patients. Based on confirmed cases the overall annual incidence increased from 6.2 to 8.9 per 100 000 persons between 2005 and 2011. In 2011 the incidences of group A, B, C and G streptococci were 3.1, 2.3, 0.9 and 2.6 per 100 000 persons, respectively. An increase was observed for all groups of BHS, but in particular for group G in men above 65 years of age. Among group A streptococci (GAS), five T-types (1, 28,12, 3,13,B3264 and B3264) represented 71% and five emm-types (1, 28, 3, 89 and 12) 76% of all isolates. Among group B streptococci (GBS) four types (III, Ia, V, Ib) represented 79% of the isolates. Potential coverage for future vaccines against GAS and GBS disease was 76% compared with the 26-valent GAS vaccine and 89% based on GBS serotypes Ia, Ib, II, III and V. The number of reported cases of invasive BHS disease increased in Denmark from 2005 to 2011. Nationwide laboratory-based surveillance of BHS is required to monitor epidemiological changes, explore potential outbreaks and determine potential vaccine coverage. BlackWell Publishing Ltd 2014-04 2013-10-29 /pmc/articles/PMC4232002/ /pubmed/24125634 http://dx.doi.org/10.1111/1469-0691.12378 Text en © 2013 The Authors Clinical Microbiology and Infection published by John Wiley and Sons on behalf of the European Society of Clinical Microbiology and Infectious Diseases. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Epidemiology
Lambertsen, L M
Ingels, H
Schønheyder, H C
Hoffmann, S
Mainardi, J-L
Danish Streptococcal Surveillance Collaboration Group 2011,
Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011
title Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011
title_full Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011
title_fullStr Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011
title_full_unstemmed Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011
title_short Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011
title_sort nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in denmark from 2005 to 2011
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232002/
https://www.ncbi.nlm.nih.gov/pubmed/24125634
http://dx.doi.org/10.1111/1469-0691.12378
work_keys_str_mv AT lambertsenlm nationwidelaboratorybasedsurveillanceofinvasivebetahaemolyticstreptococciindenmarkfrom2005to2011
AT ingelsh nationwidelaboratorybasedsurveillanceofinvasivebetahaemolyticstreptococciindenmarkfrom2005to2011
AT schønheyderhc nationwidelaboratorybasedsurveillanceofinvasivebetahaemolyticstreptococciindenmarkfrom2005to2011
AT hoffmanns nationwidelaboratorybasedsurveillanceofinvasivebetahaemolyticstreptococciindenmarkfrom2005to2011
AT mainardijl nationwidelaboratorybasedsurveillanceofinvasivebetahaemolyticstreptococciindenmarkfrom2005to2011
AT danishstreptococcalsurveillancecollaborationgroup2011 nationwidelaboratorybasedsurveillanceofinvasivebetahaemolyticstreptococciindenmarkfrom2005to2011